S625
Clinical – Head & neck
ESTRO 2026
increase in acute side effects was observed.All patients showed a clinical response to therapy with complete disappearance of lymphadenopathy in 8 patients (68%), and residual fibrotic induration of the neck in the remaining cases.CT imaging confirmed the favorable clinical evolution, demonstrating a complete response in 7 patients (58%), and post-treatment changes with possible residual disease in the others.PET-CT, performed in 11 patients, showed complete disappearance of the previos uptake in 7 (58%), and in the rest, a reduction of SUV >50 % and a tumor size reduction >50% according to RECIST criteriaWith a median follow-up of 14 months, the overall survival rate to date is 83 %. One patient died from pulmonary disease progression, and another from hepatocellular carcinoma. No cervical recurrences to date. Conclusion: Intensified Hypofractioned Radiotherapy in patients with metastatic squamous cell carcinoma of unknown primary in head and neck region appears to demonstrate superior efficacy and higher response rates compared to conventional radiotherapy regimens. Moreover, this approach offers the advantage of a shorter overall treatment course and earlier treatment initiation. Preliminary outcomes are promising References: 1.Hypofractionated radiotherapy for head and neck squamous cell carcinoma. 2.Surgery-ineligible elderly patients with cutaneous squamous cell carcinoma of the head and neck region gain clinical benefit from definitive weekly hypofractionated radiotherapy.3.Role of hypofractionated palliative radiotherapy in patients with stage four head-and-neck squamous cell carcinoma.4.Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region. 5.HYPORT: Phase 1 Study of 3-Week Hypofractionated Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma. Keywords: Hypofractioned, bulky cervical nodal metastases Cost-Effectiveness of StrataXRT for the Prevention and Management of Acute Radiation Dermatitis: An Australian Healthcare Perspective Shirley SW Tse 1,2 , Rae Blades 3 , Raymond J Chan 4 , Carmen Helena Avella Bolivar 5 , Tarek Hijal 5 , Henry CY Wong 6 , Edward Chow 7 , Hayeon Kim 8 1 Department of Oncology, United Christian Hospital, Hong Kong, Hong Kong. 2 Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. 3 Critical Care, Women and Children's Services, Digital Poster 3562
with chemotherapy or alone) influenced overall survival in both univariate (p=0.024) and multivariate (p=0.026 – hazard ratio: 0.568) analyses. Conclusion: The survival results of our study are encouraging. Nasopharyngeal cancers remain an extremely promising subject of translational research, although they remain a major public health problem in our country. Keywords: nasopharyngeal carcinoma, overall survival Hypofractioned and intensified radiotherapy for bulky nodal cervical metastases of unknown primary origin of squamous cell carcinoma Iñigo Nieto Regueira, Ana María Vílchez Simo, Xeila Bernárdez Martínez, Virginia Ochagavía Galilea Radiation Oncolgy, Complejo Hospitalario Universitario de Vigo, Vigo, Spain Purpose/Objective: Bulky nodal metastases in Head and Neck cancer, with extracapsular extension, or involvement of the carotid Digital Poster 3433 artery wall, generally preclude surgical salvage. In these patients, radioterapy is the treatment of choice, with or without concomitant chemotherapy. This group of patients presents high morbidity and mortality rates, making the prompt initiation of radiotherapy essential.The use of hypofracionated schedules increases the radical intent of treatment and shortens its overall duration, which is particulatly relevant in these patients with rapidly pregressive disese, often higly symptomatic, and with limited therapeutic alternatives. Material/Methods: In January 2023, we initiated a prospective phase II trial including 12 patients with large-volume cervical nodal metastases squamous cell carcinoma of unknown primary origin and carotid artery involvement, , HPV type 16 negative.Radiotherapy was delivery in two phases:1º. First phase: Hypofractionated VMAT treatment to the gross disease (GTV) with 2-mm margin (PTV2), administering a total dose of 25 Gy in 5 fraction of 5 Gy. 2º. Second phase: after re-simulation, and additional 50 Gy, VMAT, 1.8-2 Gy per day to the cervical nodal chains and to the gross disease (PTV1). Concomitant chemotherapyThe median follow-up period was 14 months (24- 6 months). All patients were clinically an radiologically evaluated with CT , and 11 (90%) also underwent PET
imaging Results:
All patients completed the radiotherapy. Tolerance was consistent with expectations, and no significant
Made with FlippingBook - Share PDF online